Market Overview

Jefferies Reiterates Buy Rating, $36 PT on Incyte Corporation Despite PML Case

Related INCY
Benzinga's Top Initiations
Pipeline Momentum Makes Biotech Stock Incyte Worth Watching
3 Under-The-Radar Biotech Stocks With Bullish Charts (Investor's Business Daily)

In a report published Monday, Jefferies analyst Thomas Wei reiterated a Buy rating and $36.00 price target on Incyte Corporation (NASDAQ: INCY).

In the report, Wei noted, “INCY today disclosed a 75-year old male patient developed PML, a rare brain infection, while taking Jakafi. We still believe that the overall risk-benefit profile of Jakafi is favorable and note that the causal relationship between Jakafi and the PML case is unclear with spontaneous reports of PML in the myelofibrosis literature, and there has been a favorable trend on overall survival seen in the Phase 3 trials.”

Incyte Corporation closed on Friday at $24.84.

Latest Ratings for INCY

Aug 2015BarclaysInitiates Coverage onOverweight
Aug 2015JMP SecuritiesMaintainsMarket Outperform
May 2015Bank of AmericaInitiates Coverage onBuy

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Reiteration Analyst Ratings


Related Articles (INCY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters